Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
CYTK Analyst Ratings
Strong Buy
15 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CYTK Stock 12 Month Forecast
Average Price Target
$83.07
▲(80.59% Upside)
| Highest Price Target$120.00 | Average Price Target$83.07 | Lowest Price Target$62.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Oppenheimer
Reiterated
02/28/25
Citi
Reiterated
02/28/25
Stifel Nicolaus
Reiterated
02/28/25
Piper Sandler
Reiterated
02/28/25
JMP Securities
Reiterated
02/28/25
Bank of America Securities
Reiterated
02/27/25
RBC Capital
Reiterated
02/27/25
H.C. Wainwright
Reiterated
02/27/25
Jefferies
Reiterated
02/18/25
Morgan Stanley
Upgraded
02/13/25
Evercore ISI
$65
Buy
41.30%
Upside
Initiated
02/06/25
Cytokinetics (CYTK) Receives a Buy from Evercore ISIWe launch on CYTK with an OP rating & $65 PT. We expect CTYK’s lead asset, aficamten, to go toe-to-toe with BMY’s Camzyos in the specialty cardiovascular space of hypertrophic cardiomyopathy (HCM). Afi has a valid claim to being best-in-class, although CYTK will be tasked with an educational push to sway decision makers. In the NT, we expect headwinds from competitive readouts (EWTX) & label jitters (PDUFA 09/26/25). However, we see CYTK as having ample room for upside over the LT or sooner should EWTX slip or afi obtain a clearly superior label. Either of these scenarios represent significant upside to our current estimates.
Truist Financial
$70
Buy
52.17%
Upside
Reiterated
02/06/25
Cytokinetics' Aficamten Poised for Market Success Amid Competitive Dynamics and Expanding HCM OpportunitiesWe believe this morning's weakness in CYTK shares (-7.5% CYTK vs. -0.5% XBI) is likely due to commentary from Bristol Myers Squibb's (BMY, Buy) EPS call where they highlighted an upcoming April PDUFA date where FDA will review (and potentially relax) the REMS / Echo monitoring requirement for Camzyos that competes with Cytokinetcs' aficamten. The Camzyos echocardiogram monitoring requirement in the EU was relaxed from Q12W to Q6M once patients are on a stable dose, and Bristol believes there is possibility of a similar update to the US label.
Needham
$72
Buy
56.52%
Upside
Reiterated
02/06/25
Positive Outlook for Cytokinetics Amid Rising HCM Market Demand and Developments
Mizuho Securities
$103
Buy
123.91%
Upside
Reiterated
02/06/25
Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK) and Envista Holdings (NYSE: NVST)
Leerink Partners
―
Buy
―
Reiterated
02/06/25
Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK), Insmed (NASDAQ: INSM) and IQVIA Holdings (NYSE: IQV)We believe BMY's [OP, Risinger] 4Q/FY24 earnings updates for Camzyos (mavacamten) may signal a slightly greater competitive headwind for CYTK's aficamten (afi) in obstructive hypertrophic cardiomyopathy (oHCM) because 1) Camzyos' European label was updated to reduce frequency of longer- term echo monitoring, and 2) BMY seems to be pursuing less restrictive echo monitoring for Camzyos in the US as well in the near term and thus, we are not surprised that CYTK stock closed down ~9% (vs -1% XBI). While we believe the oHCM market should be more than large enough for multiple agents, and afi's profile has other differentiators that could drive substantial adoption, we recognize that BMY's efforts to "close the gap" on REMS differentiation could have future implications for afi's commercial uptake.
Best Analysts Covering Cytokinetics
Which Analyst Should I Follow If I Want to Buy CYTK and Sell After:
1 Month
xxx
Success Rate
9/14 ratings generated profit
Average Return
+16.57%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 64.29% of your transactions generating a profit, with an average return of +16.57% per trade.
3 Months
xxx
Success Rate
11/16 ratings generated profit
Average Return
+21.94%
upgraded a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +21.94% per trade.
1 Year
Success Rate
14/16 ratings generated profit
Average Return
+88.48%
upgraded a buy rating 18 days ago
Copying Jeffrey Hung's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +88.48% per trade.
2 Years
xxx
Success Rate
15/16 ratings generated profit
Average Return
+119.90%
upgraded a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 93.75% of your transactions generating a profit, with an average return of +119.90% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CYTK Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Dec 24
Jan 25
Feb 25
Strong Buy
21
21
18
18
27
Buy
17
21
18
14
8
Hold
11
12
7
7
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
49
54
43
39
39
Each month's total comprises the sum of three months' worth of ratings.
CYTK Financial Forecast
CYTK Stock Forecast FAQ
What is CYTK’s average 12-month price target, according to analysts?
Based on analyst ratings, Cytokinetics’s 12-month average price target is $83.07.
What is CYTK’s upside potential, based on the analysts’ average price target?
Cytokinetics has 80.59% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CYTK a Buy, Sell or Hold?
Cytokinetics has a consensus rating of Strong Buy which is based on 15 buy ratings, 1 hold ratings and 0 sell ratings.
What is Cytokinetics’s price target?
The average price target for Cytokinetics is $83.07. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $120.00 ,the lowest forecast is $62.00. The average price target represents 80.59% Increase from the current price of $46.
The highest analyst price target is $120.00 ,the lowest forecast is $62.00. The average price target represents 80.59% Increase from the current price of $46.
What do analysts say about Cytokinetics?
Cytokinetics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
How can I buy shares of CYTK?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.